- Home
- VOR vs PRQR Comparison
VOR vs PRQR Comparison
Compare VOR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- PRQR
- Stock Information
- Founded
- VOR 2015
- PRQR 2012
- Country
- VOR United States
- PRQR Netherlands
- Employees
- VOR N/A
- PRQR N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- PRQR Health Care
- Exchange
- VOR Nasdaq
- PRQR Nasdaq
- Market Cap
- VOR 207.1M
- PRQR 224.4M
- IPO Year
- VOR 2021
- PRQR 2014
- Fundamental
- Price
- VOR $29.40
- PRQR $3.02
- Analyst Decision
- VOR Buy
- PRQR Strong Buy
- Analyst Count
- VOR 6
- PRQR 8
- Target Price
- VOR $85.33
- PRQR $8.88
- AVG Volume (30 Days)
- VOR 526.1K
- PRQR 626.8K
- Earning Date
- VOR 11-06-2025
- PRQR 11-06-2025
- Dividend Yield
- VOR N/A
- PRQR N/A
- EPS Growth
- VOR N/A
- PRQR N/A
- EPS
- VOR N/A
- PRQR N/A
- Revenue
- VOR N/A
- PRQR $20,129,184.00
- Revenue This Year
- VOR N/A
- PRQR N/A
- Revenue Next Year
- VOR N/A
- PRQR N/A
- P/E Ratio
- VOR N/A
- PRQR N/A
- Revenue Growth
- VOR N/A
- PRQR 8.65
- 52 Week Low
- VOR $2.62
- PRQR $1.07
- 52 Week High
- VOR $65.80
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- VOR 52.41
- PRQR 71.55
- Support Level
- VOR $28.65
- PRQR $2.60
- Resistance Level
- VOR $31.31
- PRQR $2.58
- Average True Range (ATR)
- VOR 3.26
- PRQR 0.23
- MACD
- VOR -1.89
- PRQR 0.07
- Stochastic Oscillator
- VOR 2.79
- PRQR 96.17
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.